NAGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Niagen Bioscience's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was $0.09. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.10.
Niagen Bioscience's EPS (Basic) for the three months ended in Dec. 2024 was $0.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.10.
Niagen Bioscience's EPS without NRI for the three months ended in Dec. 2024 was $0.09. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was $0.10.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Niagen Bioscience's highest 3-Year average EPS without NRI Growth Rate was 43.60% per year. The lowest was -146.60% per year. And the median was 3.70% per year.
The historical data trend for Niagen Bioscience's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
EPS (Diluted) | Get a 7-Day Free Trial |
![]() |
![]() |
-0.33 | -0.40 | -0.24 | -0.07 | 0.11 |
Niagen Bioscience Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EPS (Diluted) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | -0.01 | - | 0.02 | 0.09 |
For the Biotechnology subindustry, Niagen Bioscience's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's PE Ratio distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Niagen Bioscience's Diluted EPS for the fiscal year that ended in Dec. 2024 is calculated as
Diluted EPS (A: Dec. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (8.55 | - | 0) | / | 78.125 | |
= | 0.11 |
Niagen Bioscience's Diluted EPS for the quarter that ended in Dec. 2024 is calculated as
Diluted EPS (Q: Dec. 2024 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (7.179 | - | 0) | / | 82.088 | |
= | 0.09 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (NAS:NAGE) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Niagen Bioscience's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Jaksch Frank L Jr | director, 10 percent owner, officer: Chief Executive Officer | 10005 MUIRLANDS BOULEVARD, SUITE G FIRST FLOOR, IRVINE CA 92618 |
Kristin Patrick | director | 3329 CAY DRIVE, SHERMAN OAKS CA 91423 |
Brianna Gerber | officer: SVP Finance / Interim CFO | C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782 |
Champion River Ventures Ltd | 10 percent owner | C/O 7F, CHEUNG KONG CENTER, 2 QUEEN'S ROAD, CENTRAL K3 00000 |
Robert N Fried | director | 100 NORTH CRESCENT DRIVE, BEVERLY HILLS CA 90210 |
Steven D Rubin | director | OPKO HEALTH, INC., 4400 BISCAYNE BLVD., MIAMI FL 33137 |
Li Ka Shing | 10 percent owner | 79 DEEP WATER BAY ROAD, HONG KONG F4 00000 |
Chau Hoi Shuen Solina Holly | 10 percent owner | SUITES PT. 2909 & 2910, HARBOUR CENTRE, 25 HARBOUR ROAD, WANCHAI K3 999077 |
Hamed Shahbazi | director | C/O CHROMADEX, INC., 1735 FLIGHT WAY, SUITE 200, TUSTIN CA 92782 |
Ann Cohen | director | C/O CHROMADEX CORPORATION, 10900 WILSHIRE BLVD. STE 600, LOS ANGELES CA 90024 |
Ng Wang Yu Gary | director | ROOM 1709 HARBOUR CENTER, 25 HARBOUR ROAD, WANCHAI K3 - |
Caroline S Levy | director | 2424 N FEDERAL HIGHWAY, SUITE 208, BOCA RATON FL 33431 |
Stephen A Block | director | INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 WEST 57TH ST, NEW YORK NY 10019 |
Lisa Hatton Harrington | officer: General Counsel | 53 SEA TERRACE, NEWPORT COAST CA 92657 |
Kevin M Farr | officer: Chief Financial Officer | MATTEL, INC., 333 CONTINENTAL BLVD, M1-1518, EL SEGUNDO CA 90245 |
From GuruFocus
By GuruFocus News • 03-05-2025
By Business Wire • 12-03-2024
By Business Wire • 09-10-2024
By GuruFocus News • 10-31-2024
By Business Wire • 09-09-2024
By Business Wire • 11-14-2024
By Business Wire • 01-06-2025
By Business Wire • 03-11-2025
By Business Wire • 10-15-2024
By Business Wire • 03-20-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.